KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.96

Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.

Alejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, Alvaro Juarez Soto, Beatriz Garcillan, Cristian Vidal, Joana Lencart, Amitabha Bhaumik, Suneel D Mundle, Suzy Van Sanden, Kim N Chi, Anders Bjartell, Neeraj Agarwal, Axel S Merseburger

Eur Urol Oncol 8(5) 1311-1320

PMID41027802
PMCID-
DOI10.1016/j.euo.2025.07.002
发表日期2025-09-30
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND AND OBJECTIVE: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with high disease burden. METHODS: Patients were assessed in subgroups of those with four to fewer than ten, ten to <20, or ≥20 bone metastases; with lung but not liver metastases; and with no/mild or moderate/severe pain at baseline. Prostate-specific antigen (PSA) response, overall survival (OS), other endpoints, and safety were assessed using descriptive statistics, Kaplan-Meier method, and Cox proportional hazard model. KEY FINDINGS AND LIMITATIONS: Higher proportions of patients receiving apalutamide than those receiving placebo achieved a deep PSA response of ≤0.2 ng/ml at 3, 6, and 12 mo of treatment initiation regardless of the disease burden. OS benefit favored apalutamide plus ADT versus ADT alone in all bone metastasis subgroups: four to fewer than ten (hazard ratio [HR]: 0.68 [95% confidence interval 0.44-1.03]; p = 0.07), ten to <20 (0.61 [0.37-1.00]; p = 0.048), or ≥20 (0.53 [0.39-0.72]; p < 0.001) bone metastases. Addition of apalutamide to ADT was beneficial across other endpoints and in patients with lung but no liver metastases and regardless of pain at baseline. No new safety signals were observed across subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: These findings provide strong evidence for early intensification with apalutamide plus ADT in patients with mHSPC regardless of the disease burden.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。